Remedy Entertainment Oyj (HEL:REMEDY)

Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 163.09 million. The enterprise value is 151.96 million.

Market Cap	163.09M
Enterprise Value	151.96M

Important Dates

The next confirmed earnings date is Tuesday, May 5, 2026.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.64% in one year.

Current Share Class	13.59M
Shares Outstanding	13.59M
Shares Change (YoY)	+0.64%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	32.80%
Owned by Institutions (%)	20.90%
Float	9.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.74
PB Ratio	2.88
P/TBV Ratio	5.69
P/FCF Ratio	245.61
P/OCF Ratio	36.14
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.47, with an EV/FCF ratio of 228.85.

EV / Earnings	-11.66
EV / Sales	2.55
EV / EBITDA	35.47
EV / EBIT	n/a
EV / FCF	228.85

Financial Position

The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.32.

Current Ratio	3.25
Quick Ratio	3.25
Debt / Equity	0.32
Debt / EBITDA	4.26
Debt / FCF	27.51
Interest Coverage	0.04

Financial Efficiency

Return on equity (ROE) is -20.83% and return on invested capital (ROIC) is 0.14%.

Return on Equity (ROE)	-20.83%
Return on Assets (ROA)	0.04%
Return on Invested Capital (ROIC)	0.14%
Return on Capital Employed (ROCE)	0.08%
Weighted Average Cost of Capital (WACC)	9.41%
Revenue Per Employee	153,773
Profits Per Employee	-33,669
Employee Count	387
Asset Turnover	0.64
Inventory Turnover	n/a

Taxes

Income Tax	-2.67M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.74% in the last 52 weeks. The beta is 1.00, so HEL:REMEDY's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-7.74%
50-Day Moving Average	13.62
200-Day Moving Average	14.32
Relative Strength Index (RSI)	42.95
Average Volume (20 Days)	10,830

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 59.51 million and -13.03 million in losses. Loss per share was -0.96.

Revenue	59.51M
Gross Profit	47.27M
Operating Income	56,000
Pretax Income	-15.70M
Net Income	-13.03M
EBITDA	2.95M
EBIT	56,000
Loss Per Share	-0.96

Balance Sheet

The company has 29.40 million in cash and 18.27 million in debt, with a net cash position of 11.13 million or 0.82 per share.

Cash & Cash Equivalents	29.40M
Total Debt	18.27M
Net Cash	11.13M
Net Cash Per Share	0.82
Equity (Book Value)	56.59M
Book Value Per Share	4.16
Working Capital	31.00M

Cash Flow

In the last 12 months, operating cash flow was 4.51 million and capital expenditures -3.85 million, giving a free cash flow of 664,000.

Operating Cash Flow	4.51M
Capital Expenditures	-3.85M
Depreciation & Amortization	2.89M
Net Borrowing	-1.44M
Free Cash Flow	664,000
FCF Per Share	0.05

Margins

Gross margin is 79.43%, with operating and profit margins of 0.09% and -21.90%.

Gross Margin	79.43%
Operating Margin	0.09%
Pretax Margin	-26.39%
Profit Margin	-21.90%
EBITDA Margin	4.96%
EBIT Margin	0.09%
FCF Margin	1.12%

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.64%
Shareholder Yield	-0.64%
Earnings Yield	-7.99%
FCF Yield	0.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEL:REMEDY has an Altman Z-Score of 4.95 and a Piotroski F-Score of 6.

Altman Z-Score	4.95
Piotroski F-Score	6